GlassScriptPhysician profile
Tracy L Kerzan
NPI 1629529334
$1,883.15
in general payments reported to CMS, 2019-2025
28 companies · $553 in 2025
The $553 reported for 2025 was more than what 85% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
See the full distribution for Critical Care Medicine (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $321 · 2023: $157 · 2024: $688 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $339.16 | 2021-2025 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.33 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $183.85 | 2024-2025 | Verquvo, Capvaxive |
| Mylan Specialty L.P. | $157.69 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.26 | 2021-2025 | Jardiance, Ofev |
| Amgen INC. | $122.14 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $83.36 | 2021-2024 | Nucala |
| Insmed, INC. | $80.62 | 2024-2025 | Arikayce, Brinsupri |
| Bayer Healthcare Pharmaceuticals INC. | $51.99 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $47.94 | 2024 | Arcalyst |
| Genzyme Corporation | $46.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $45.02 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $44.25 | 2024-2025 | Farxiga |
| Pfizer INC. | $43.44 | 2021-2025 | |
| Novo Nordisk INC | $43.24 | 2024-2025 | Wegovy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $35.30 | 2024-2025 | Glassia |
| Grifols USA, LLC | $27.45 | 2022-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $26.50 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Abbott Laboratories | $23.23 | 2023 | Cardiomems |
| United Therapeutics Corporation | $19.16 | 2025 | Tyvaso |
| Otsuka America Pharmaceutical, INC. | $17.62 | 2022 | |
| Verona Pharma, INC. | $17.61 | 2025 | Ohtuvayre |
| Resmed Corp | $17.17 | 2022 | |
| Amarin Pharma, INC. | $14.38 | 2021 | |
| Baxter Healthcare | $14.00 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $13.86 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $13.18 | 2022 | |
| Fresenius USA Marketing, INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Kerzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.